Jürgen Karl-Josef Hescheler (born 2 May 1959) is a German physician and stem cell researcher. He is director to the Institute for Neurophysiology and a university professor at the University of Cologne.[1] Hescheler has studied the biology of embryonic stem cells since the late 80's,[2] and his publications have garnered an average total of over 1,000 citations per year since the late 2010's.[3] He became the first researcher to accomplish an electrophysiological characterization of stem cells and was also among the first scientists in Germany obtaining permission to do research on human embryonic stem cells.[4]. He is the founder and Chairman of the German Society for Stem Cell Research (GSZ)

Career

Prof. Hescheler obtained his doctoral degree from Saarland University in 1985 and continued his research on Ca2+ currents until his Habilitation in the year 1988. He was appointed Director of the Institute for Neurophysiology at the University of Cologne in 1994. Hescheler has since held positions at multiple research institutions, including: Visiting Professor at University of Vermont (USA, 1992) and at Tongji Medical University, in Wuhan (China, 1998), President of confidants of the German National Academic Foundation (2000), appointments at the University of Texas, Houston (USA, 2001) and University of Xian (China, 2003), and Founder and President of the German Society for Stem Cell Research (2004). He has been appointed as the Coordinator of various pan-European consortia including the large-scale integrated EU-projects FunGenES ("Functional Genomics of Engineered Embryonic Stem Cells), CRYSTAL ("Cryo-banking of stem cells for human Therapeutic Application"), ESNATS ("Embryonic stem cell-based Novel Alternative Testing Strategies"), and DETECTIVE - Detection of endpoints and biomarkers for repeated dose toxicity using in vitro systems. In 2009, he was awarded an Honorary Doctorate Dr. h.c. by the Tongji Medical College in Wuhan, China.

Hescheler began studying cellular signal transduction in embryonic stem cells in the late 1980's, with a focus on defining signalling pathways in different cells (g-protein phosphorylation, electrophysiology of channels). In 1991, he and his colleague achieved a first functional characterization of cardiomyocytes developed from embryonic stem cells,[5] an achievement which may have ultimately supported the use of embryonic stem cells in regenerative medicine. In 2002, he was among the first scientists in Germany to obtain permission to work with human embryonic stem cells.

As the current Chairman and Director to the Institute for Neurophysiology at the University of Cologne, Hescheler's research areas include work on embryonic and adult stem cells, induced pluripotent stem cells, mesenchymal stem cells and germline pluripotent stem cells; his research programs are aimed towards promoting the use of stem cells for translational purposes, including clinical applications. Hescheler promotes the vision of EPAA through innovative alternative testing strategies, applying stem cells towards toxicity testing. In addition to the objective of advancing the principles of Reduction, Refinement, and Replacement (3R) in research, the aim of these efforts is to coordinate a multidisciplinary research initiative involving multiple projects and consortia. This ultimate goal is to establish a mechanistic-driven, predictive approach in toxicology, shifting it away from its primarily descriptive nature towards a more evidence-based understanding of long-term toxic effects, rooted in pathways and mechanisms.

Hescheler has been appointed coordinator of various European Consortia such as FunGenES, CRYSTAL, and more recently ESNATS and DETECTIVE. He is also coordinator of the BMBF consortium “iPS and adult bone marrow cells for cardiac repair.” In 2004 he founded and has since chaired the German Society of Stem Cell Research (GSZ). He is an active member of the Scientific Panel of the AXLR8 Consortium and a member of steering committee of Stem Cell Network North Rhine Westphalia.

Hescheler has engaged in research collaborations with the following European institutions:

  • UK - National Biological Standards Board/UK Stem Cell Bank
  • Switzerland - University of Geneva, Faculty of medicine, ENKAM Pharmaceuticals
  • France - INSERM
  • Belgium - Vrije Universiteit Brussel/Department of Toxicology
  • Netherlands - University of Maastricht, Academic Medical Centre Amsterdam/Department of Anatomy and Embryology
  • Romania - Institute for Biologic and Cellular Pathologies
  • Portugal - ITQB/IBET
  • Hungary - Biotalentum
  • Ukraine - National University of Kyiv-Mohyla Academy

Non-European collaborations include those through the following institutions:

  • Brazil - Universidade de São Paulo
  • USA - University of Pittsburgh, Department of pharmacology, Medical University of South Carolina,
  • Egypt - Cairo University
  • Cameroon - University of Yaounde, University of Dschang
  • China - Huazhong University of Science and Technology, Tongji Medical College, Department of Physiology
  • India - Tulip Bio-med Solutions limited

Awards

He received several awards for alternative testing research, including the Bundesminister für Jugend, Familie, Frauen und Gesundheit Award (1992), the Hildegard Doerenkamp Gerhard Zbinden Foundation Award (1992), the Dorothy Hegarty Award (1999) and an Honorary Doctorate of the Tongji Medical Faculty of the Huazhong University in Wuhan (China) (2009).

Projects

EU Projects coordinated

1. DETECTIVE – Detection of endpoints and biomarkers of repeated dose toxicity using in vitro systems

http://www.detect-iv-e.eu/?page_id=319

2. DETECTIVE is a key building block of the SEURAT-1 cluster (Safety Evaluation Ultimately Replacing Animal Testing)

https://web.archive.org/web/20130308083355/http://www.seurat-1.eu/pages/partners-and-people/who-is-who.php

3. Embryonic stem cell-based novel alternative testing strategies

http://www.esnats.eu/index.php/about-esnats/consortium-partners/UKK

4. CRYo-banking of Stem cells for human therapeutic application (completed)

https://web.archive.org/web/20160304064736/http://www.crystal-eu.org/university_of_cologn.html

BMBF projects

1. Pluripotent Cells for Heart Therapies

http://www.gesundheitsforschung-bmbf.de/en/1195.php#Pluripotent

2. Mesenchymal stem cell mediated preconditioning of human islets

http://www.gesundheitsforschung-bmbf.de/en/1195.php#Mesenchymal

As Partner in EU Projects

1. diXa: Data Infrastructure for Chemical Safety

http://www.dixa-fp7.eu/home

2. STEMCAM: A IAPP on the Role of NCAM in Stem Cell Differentiation

http://stemcam.biotalentum.eu/partners/ukk

3. INFARCT CELL THERAPY: Therapy after Myocardial Infarction: repair by stem and progenitor cell mobilization and transfer

http://www.meduniwien.ac.at/typo3/index.php?id=6157

4. HYPERLAB High yield and performance stem cell lab

http://www.hyperlab.eu/index.php

References

  1. ↑ "Jürgen Karl-Josef Hescheler | Surgical Pathology 2017 | Conferenceseries Ltd". surgicalpathology.insightconferences.com. 2017-03-27. Retrieved 2023-05-16.
  2. ↑ "Neurophysiologie". physiologie.uni-koeln.de. Retrieved 2023-05-16.
  3. ↑ "ResearchGate Profile: Jürgen Hescheler". October 17, 2023.
  4. ↑ "Neurophysiologie". physiologie.uni-koeln.de. Retrieved 2023-05-16.
  5. ↑ Wobus, Anna M.; Wallukat, Gerd; Hescheler, Jürgen (December 1991). "Pluripotent mouse embryonic stem cells are able to differentiate into cardiomyocytes expressing chronotropic responses to adrenergic and cholinergic agents and Ca2+ channel blockers". Differentiation. 48 (3): 173–182. doi:10.1111/j.1432-0436.1991.tb00255.x. PMID 1725163.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.